For me, I read data the way you would read the words of an anecdote
( Source ) The continued growth in uptake of GLP-1 agonists is uncertain
Public Sources & References Europe PMC europepmc.org 5 records ClinicalTrials.gov clinicaltrials.gov 3 records PubChem pubchem.ncbi.nlm.nih.gov A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) ClinicalTrials.gov Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes ClinicalTrials.gov Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke ClinicalTrials.gov Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Excess weight can cause secondary health issues to occur, but it can be difficult to lose weight with exercise and diet alone
Without controlled studies, we cannot know whether observed improvements result from the treatment itself, placebo effects, natural weight fluctuation, or simple photograph manipulation
Links: By understanding the research on the differences between Semaglutide and Tirzepatide, we hope you will be able to choose the right peptide for your study